



Driving Biopharmaceutical Advancements of Plant-derived Cannabinoid-based Products

Avicanna is a commercial stage, diversified and vertically-integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for global consumer, medical cannabis, and pharmaceutical market segments.

Advanced Product Lines

- **Pura H&W™**: an innovative, clinically tested line of CBD consumer derma-cosmetic products*
- **RHO Phyto™**: an advanced line of medical cannabis products in various deliveries and ratios of CBD and THC
- **Pharmaceuticals drugs**: Various indication specific cannabinoid based drugs in clinical development and registration phase

An Established Leader in Cannabinoid Research and Development

R&D headquarters at JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District. World-class research and clinical collaborations with leading Canadian academic and medical institutions. In addition to a burgeoning pharmaceutical pipeline, Avicanna's team of experts have developed and commercialized several industry leading product lines.

World-Class Vertical Integration

Cultivation, Extraction, Purification, Production and Manufacturing




Two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. These sustainable, economical, and industrial scale subsidiaries allow Avicanna to cultivate, process, and commercialize a range of cannabis and hemp cultivars dominant in CBD, CBG, THC for use as active pharmaceutical ingredients.

Q3-2020 launch nation-wide in Canada in partnership with:



RHO Phyto™: Medical cannabis - CBD and CBD/THC

- Complete, consistent, and scientifically advanced medical cannabis formulary
- Now commercial in Canada in partnership with Medical Cannabis by Shoppers and expanding into retail sales in Q1-2021
- Now commercial in Colombia under a magisterial prescription model
- Advanced formulations with stability and pre-clinical data demonstrating enhanced bioavailability



*Expected to be marketed as Pura Earth in Canada. Pura Earth products in Colombia are being rebranded to Pura H&W

Fast Facts – January 4, 2020

Ticker (Exchange)	AVCN (TSX) AVCNF (OTCQX) ONN (Frankfurt)
Stock Price (CAD)	\$1.20
Market Cap	\$42M
Outstanding Shares	35.9M
52-Week Range	\$0.63 - \$3.00

All figures as of close of trading January 4th 2020

Investment Highlights

- Four consecutive quarters of double digit + increase in revenue and cost reductions
- Commercial stage and diversified revenue streams, across global markets including Canada, US, UK and LATAM
- Agreement with Medical Cannabis by Shoppers, for the distribution of RHO Phyto products across Canada
- Proprietary R&D, preclinical and clinical platforms including 3 years of IP development, team of 10+ scientists and world-class clinical collaborations
- R&D headquarters at JLABS @ Toronto in MaRS Discovery District, inside the Johnson & Johnson Innovation Centre
- Proprietary cannabinoid product lines addressing consumer retail, medical cannabis and Rx markets, including Pura H&W™ and RHO Phyto™
- Pharmaceutical pipeline of dermatology, neurology, oncology and pain management products
- World-class vertical integration, cultivation, extraction, purification, production, and manufacturing (global GMP Certifications)
- Low cost and sustainable cultivation, with 480,000 sq ft in Santa Marta, Colombia



Pura H&W: CBD Consumer Retail Products

Functional and evidence-based CBD derma-cosmetics addressing the emerging global CBD cosmetics segment. Utilizing a scientific approach, advanced products and supported by completed clinical studies.



PRODUCT EXPECTATIONS*

Q4-2019	Colombia	57 retailers and several e-commerce platforms†
	USA	in partnership with Red White and Bloom
H1-2021	Canada	in partnership with Medical Cannabis by Shoppers™†
	EU	e-commerce
	Brazil** + Ecuador	

*Product launch expectations conditional upon regulatory approvals. †Expected to be marketed as Pura Earth in Canada. Pura Earth products in Colombia are being rebranded to Pura H&W. **Expect to market the products that were subject to the clinical studies as medical cannabis products under private label.

Proprietary Clinical Development Platform

With ongoing clinical trials on its medical cannabis (RHO Phyto) and pharmaceutical pipeline products, Avicanna's commitment to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company's vision since its inception.

All Clinical Projects	Pre-Clinical	Protocol Development	Ethics Approval	Clinical Study	Registration
Cosmetic Trials					
Eczema-prone Skin				Completed	Completed**
Acne-prone Skin				Completed	Completed**
Anti-Aging				Completed	Completed**
Real-World Evidence (RHO Phyto)					
Pain, sleep, depression				Commenced	
Epilepsy					
Epidermolysis Bullosa					
Pharmaceutical Trials					
Chronic pain & Opioid-sparing				Phase II	
Epidermolysis Bullosa*				Phase II	
Prevalence of Neuropathic Pain in Sickle Cell Disease				Completed	
Neuropathic Pain in Sickle Cell Disease*					
Inflammation related to COVID-19					
Osteoarthritis					

*Phase I studies not required for this product; Pending regulatory approval.

** Cosmetic product registration in Colombia and EU

H1-2021

- ▶ Launch RHO Phyto across retail channels in Canada
- ▶ Commercialize Pura H&W in the UK and USA
- ▶ Commercialize Pura Earth in Canada and Ecuador
- ▶ Indication specific drug registration in Colombia
- ▶ Commence export of RHO Phyto into LATAM and EU

H2-2021

- ▶ Indication specific drug registrations in Brazil and Ecuador
- ▶ Conclude RWET's on RHO Phyto
- ▶ Commence Phase II trials on Epidermolysis Bullosa
- ▶ Expand RHO Phyto and Pura H&W to other LATAM markets

Recent News

- Dec 23rd, 2020 - Avicanna to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada
- Dec 17th, 2020 - Avicanna Expands Distribution Network in South America Through Commercial Partnerships in Ecuador and Commercial Export of Feminized Seeds to Uruguay
- Dec 10th, 2020 - Avicanna Launches Medical Cannabis Program with its RHO Phyto™ Formulary Nationwide in Colombia
- Dec 8th, 2020 - Avicanna Announces Closing of Public Offering of Units

Executive Management Team

Aras Azadian

CEO, Director, and Co-Founder

Setu Purohit

President, Director, and Co-Founder

Dave Sohi

Chief Financial Officer

Dr. Amza Ali

Chief Medical Officer

Lucas Nosiglia

CAO and President of LATAM

Dr. Justin Grant

EVP Scientific Affairs

Ivana Maric

EVP Marketing

Investor Contact

ir@avicanna.com

Company Contact

Avicanna Inc.

480 University Ave, Suite 1502

Toronto, ON M5G 1V2 Canada

P: (647) 243-5283

www.Avicanna.com

This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. Certain information contained herein and certain oral statements made are forward-looking and relate to Avicanna Inc.'s ("Avicanna") business strategy, product development, timing of product development, events and courses of action. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, milestones, expectations or intentions regarding the future including words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to" or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements about anticipated dates for revenue recognition; anticipated dates for product launches; our plans for future products and enhancements of existing products; designs for future product packaging; expected completion dates for clinical trials and product development; expected results of clinical trials; the granting of any certifications, licenses, or registrations; our future growth strategy; our future intellectual property, research and development, product formulations and business lines; intended quality standards of our joint venture with Sigma Analytics; each of our expected upcoming milestones; and our anticipated trends and challenges in the markets in which we operate. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna will operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, expected outcomes for clinical trials, the timely completion of research and development initiatives and the price of cannabis and cannabis related products. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect.